519 related articles for article (PubMed ID: 26391465)
1. Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results.
Wykoff CC; Croft DE; Brown DM; Wang R; Payne JF; Clark L; Abdelfattah NS; Sadda SR;
Ophthalmology; 2015 Dec; 122(12):2514-22. PubMed ID: 26391465
[TBL] [Abstract][Full Text] [Related]
2. Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: 2-Year Results of the TREX-AMD Study.
Wykoff CC; Ou WC; Brown DM; Croft DE; Wang R; Payne JF; Clark WL; Abdelfattah NS; Sadda SR;
Ophthalmol Retina; 2017; 1(4):314-321. PubMed ID: 31047517
[TBL] [Abstract][Full Text] [Related]
3. Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study.
Kertes PJ; Galic IJ; Greve M; Williams RG; Rampakakis E; Scarino A; Sheidow T
Ophthalmology; 2019 Jun; 126(6):841-848. PubMed ID: 30677465
[TBL] [Abstract][Full Text] [Related]
4. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
Brown DM; Chen E; Mariani A; Major JC;
Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
[TBL] [Abstract][Full Text] [Related]
5. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial.
Abdelfattah NS; Al-Sheikh M; Pitetta S; Mousa A; Sadda SR; Wykoff CC;
Ophthalmology; 2017 Feb; 124(2):215-223. PubMed ID: 27863845
[TBL] [Abstract][Full Text] [Related]
6. Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes.
Payne JF; Wykoff CC; Clark WL; Bruce BB; Boyer DS; Brown DM;
Am J Ophthalmol; 2019 Jun; 202():91-99. PubMed ID: 30771333
[TBL] [Abstract][Full Text] [Related]
7. Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes.
Payne JF; Wykoff CC; Clark WL; Bruce BB; Boyer DS; Brown DM;
Ophthalmology; 2017 Jan; 124(1):74-81. PubMed ID: 27836430
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.
Berg K; Pedersen TR; Sandvik L; Bragadóttir R
Ophthalmology; 2015 Jan; 122(1):146-52. PubMed ID: 25227499
[TBL] [Abstract][Full Text] [Related]
9. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P;
Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
[TBL] [Abstract][Full Text] [Related]
10. Effect of posterior vitreous detachment on treat-and-extend versus monthly ranibizumab for neovascular age-related macular degeneration.
Waldstein SM; Coulibaly L; Riedl S; Sadeghipour A; Gerendas BS; Schmidt-Erfurth UM
Br J Ophthalmol; 2020 Jul; 104(7):899-903. PubMed ID: 31563866
[TBL] [Abstract][Full Text] [Related]
11. A systematic review to assess the 'treat-and-extend' dosing regimen for neovascular age-related macular degeneration using ranibizumab.
Rufai SR; Almuhtaseb H; Paul RM; Stuart BL; Kendrick T; Lee H; Lotery AJ
Eye (Lond); 2017 Sep; 31(9):1337-1344. PubMed ID: 28475181
[TBL] [Abstract][Full Text] [Related]
12. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL
JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617
[TBL] [Abstract][Full Text] [Related]
13. Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study.
Silva R; Berta A; Larsen M; Macfadden W; Feller C; Monés J;
Ophthalmology; 2018 Jan; 125(1):57-65. PubMed ID: 28893454
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.
Khanani AM; Patel SS; Ferrone PJ; Osborne A; Sahni J; Grzeschik S; Basu K; Ehrlich JS; Haskova Z; Dugel PU
JAMA Ophthalmol; 2020 Sep; 138(9):964-972. PubMed ID: 32729897
[TBL] [Abstract][Full Text] [Related]
15. Randomized Trial of Monthly Versus As-Needed Intravitreal Ranibizumab for Radiation Retinopathy-Related Macular Edema: 1-Year Outcomes.
Schefler AC; Fuller D; Anand R; Fuller T; Moore C; Munoz J; Kim RS;
Am J Ophthalmol; 2020 Aug; 216():165-173. PubMed ID: 32278771
[TBL] [Abstract][Full Text] [Related]
16. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM
Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results.
Payne JF; Wykoff CC; Clark WL; Bruce BB; Boyer DS; Brown DM;
Br J Ophthalmol; 2021 Feb; 105(2):253-257. PubMed ID: 32303499
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
Sahni J; Dugel PU; Patel SS; Chittum ME; Berger B; Del Valle Rubido M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Weikert R; Fauser S
JAMA Ophthalmol; 2020 Sep; 138(9):955-963. PubMed ID: 32729888
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial.
Jackson TL; Soare C; Petrarca C; Simpson A; Neffendorf JE; Petrarca R; Muldrew A; Peto T; Chakravarthy U; Membrey L; Haynes R; Costen M; Steel D; Desai R;
JAMA Ophthalmol; 2020 Aug; 138(8):835-842. PubMed ID: 32644148
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
Schmidt-Erfurth U; Kaiser PK; Korobelnik JF; Brown DM; Chong V; Nguyen QD; Ho AC; Ogura Y; Simader C; Jaffe GJ; Slakter JS; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Sowade O; Zeitz O; Norenberg C; Sandbrink R; Heier JS
Ophthalmology; 2014 Jan; 121(1):193-201. PubMed ID: 24084500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
